New immunodeficiency drug delays the onset of type 1 diabetes

Health and Medical

A major study on a new drug used to inhibit immunity may delay the onset of type 1 diabetes.

According to the site of the newspaper "Daily Mail," the British found a drug that inhibits low levels of immunity and contains the active ingredient "Teplizumab", Allows the body to continue making insulin, and this has stopped the development of diabetes for nearly two years.

Unlike type 2 diabetes, the first type has no relation to lifestyle and is instead linked to heredity.

"Type 1 diabetes affects many people, especially children, and delaying the disease is important," said Professor Kevin Hurold, who led the Yale study.

The researchers tested 76 patients, most of them aged 8 to 18, all of whom were considered to be very dangerous because relatives had diabetes.

The cure is "Teplizumab" – which is given daily by drip for two weeks – works by avoiding the destruction of insulin-producing cells.

Dr Elizabeth Robertson, a professor of diabetes treatment in the UK, said the study was "incredibly exciting" because it studied the root cause of a disease that affects 400,000 Britons.

Robertson said there must be a cure for this deadly disease, which also destroys the lives of children and adults.